Symphogen and Meiji Seika Kaisha Partner on Recombinant pAB Product
Product candidate to target a bacterial pathogen.!--h2>
Symphogen and Meiji Seika Kaisha entered into a research, development, and commercialization related to a bacterial pathogen that the companies have not disclosed. Symphogen will use its antibody discovery technology, Symplex™, to develop a fully human recombinant polyclonal antibody (pAb) product candidate that targets this pathogen.
Meiji has agreed to fund the development costs associated with the program. Symphogen will receive an initial technology access fee from Meiji and is eligible to receive development milestone payments and royalties on worldwide net sales from any successfully developed products. Symphogen has retained certain co-development option rights in the U.S. and E.U.